Nasdaq Issues Delisting Notice to Enlivex Ltd.
The company faces removal from the exchange after its shares failed to meet the required minimum bid price.
Updated on Oct. 27, 2026 in Public Companies
Live Poll
Does receiving a delisting notice from a major stock exchange change your trust in a company?
The Nasdaq Stock Market has issued a delisting notice to Enlivex Ltd. after the company's ordinary shares remained below the $1.00 minimum bid price for 30 consecutive business days.
Why it matters
The notice highlights the challenges faced by the company in maintaining its standing on the exchange, despite efforts to adjust its share structure.
The company's shares failed to maintain a $1.00 minimum bid price over a 30-business-day observation period. Enlivex also implemented a 1-for-16 reverse share split on October 27, 2026, as part of its capital restructuring efforts.
The players
Enlivex Ltd.
This is a clinical-stage immunotherapy company headquartered in Nes-Ziona, Israel, that focuses on developing treatments for immune-related diseases.
Nasdaq Stock Market
This is a global American stock exchange that sets strict listing requirements for companies to remain on its marketplace.
Nasdaq Hearings Panel
This independent body reviews appeals from listed companies facing potential delisting to determine if they can return to compliance.
The details
Enlivex, based in Nes-Ziona, Israel, is ineligible for the standard 180-day compliance period because it executed a reverse share split within the past year. The firm plans to contest the notice by requesting an oral hearing, which will pause any immediate suspension or delisting actions.
Timeline
The 30-day monitoring window for bid prices concluded prior to October 22, 2026.
The Nasdaq delisting notice was issued on October 26, 2026.
A 1-for-16 reverse share split took effect on October 27, 2026.
Market Landscape
This delisting process underscores the intense regulatory scrutiny facing smaller publicly traded firms that fail to maintain minimum valuation thresholds. It positions Enlivex within a wider group of companies struggling to satisfy exchange criteria amid volatile market performance.
Investors holding Enlivex shares may face increased volatility or liquidity risks as the company navigates the formal appeal process with the exchange. The pending hearing status means no immediate change in share availability has occurred for current stockholders.
The takeaway
Companies facing delisting often turn to reverse share splits to artificially boost their bid price and avoid removal from major exchanges. Investors should monitor the upcoming hearing closely, as outcomes from these panels can vary significantly based on the company's submitted remediation plans.
Further reading
For more information on market regulation, see Public Companies.
Live Poll
Does receiving a delisting notice from a major stock exchange change your trust in a company?
